arrow
C

Claudia Omarini

Università di Modena e Reggio Emilia
H指数:17
被引数:1,262

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2-positive early breast cancer: real-world data from NeoPowER study

新辅助帕妥珠单抗、曲妥珠单抗和标准化疗治疗HER2-positive早期乳腺癌的安全性和有效性分析: 来自NeoPowER研究的真实数据

2024-06-151
OAAI
CDK4/6 inhibitors in advanced breast cancer (aBC). Preliminary results of the CDK4/6i choice and sequence of treatments in a series of 174 patients. GOIRC-04-2019 retro/prospective observational study
2024-05-020
PRE
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy

新辅助化疗后无病理完全缓解的三阴性乳腺癌患者复发的预测因素

2022-12-019
OAAI
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib
BREAST
IF7.9
2022-12-0115
OAAI
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting

不同的HR表达模式显着影响转移性HER2乳腺癌的临床行为以及在现实世界环境中从新型anti-HER2药物中获益的程度

2019-08-075
OAAI